Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Novanta Inc. (NOVT) SEC Filings & Earnings Calls

EquiReason read 16 Novanta Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-05 — Novanta reported Q2 2026 revenue of $265.8M (+10.3% YoY) and operating income of $18.1M (+21.1% YoY), with strong growth in both segments and a major acquisition of Riverpoint Medi.

Source: SEC EDGAR filings · figures as of 2026-07-03 · read by EquiReason

NOVTNovanta Inc.Follow NOVT — free
Scientific & Technical Instruments · Technology
—
Price chart with a free account
Market cap
5.3B
P/E TTM
89.7
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

5 Aug 202610-QNovanta reported Q2 2026 revenue of $265.8M (+10.3% YoY) and operating income of $18.1M (+21.1% YoY), with strong growth in both segments and a major acquisition of Riverpoint Medical.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$266M+10% y/y
Gross Profit Margin - Automation Enabling Technologies · Automation Enabling Technologies · Q2-202652.6%
Gross Profit Margin - Medical Solutions · Medical Solutions · Q2-202638.8%
Operating Income · Q2-2026$18M+21% y/y
Net Cash Provided by Operating Activities · H1-2026$117M
Cash and Cash Equivalents · 2026-07-03$719M
Diluted Earnings Per Share · Q2-2026$0.30

Risks flagged

Tariff cost pressure

“Tariffs imposed by the U.S. government on imports from certain countries, including China, continue to put pressure on our cost to serve customers.” · word for word

Geopolitical supply chain disruption

“The conflict arising from coordinated US and Israeli military strikes on Iran beginning in February 2026, and Iran's subsequent retaliatory actions, including the temporary closure of the Strait of Hormuz, has contributed to increased global energy prices, heightened supply chain uncertainty, and rising freight and commodity costs.” · word for word

Integration risk from large acquisition

“On July 23, 2026, we completed the acquisition of all outstanding equity interests of the parent company of Riverpoint Medical for total upfront cash consideration of $1.2 billion.” · word for word

Medical Solutions margin pressure

“Medical Solutions segment gross profit margin was 38.8% for the three months ended July 3, 2026, versus a gross profit margin of 41.5% for the prior year period. The decrease in gross profit margin was primarily due to changes in product mix and temporary cost increases incurred as part of our operational transformation.” · word for word
Read the original on SEC EDGAR ↗
5 Aug 20268-K · 2.02Q2 2026 revenue $266M (+10% YoY), adjusted EBITDA $61M (+16%), both above expectations; guidance raised for Q3 and FY2026; Riverpoint Medical acquisition closed.open

Figures in the filing · each found in the filing text

Revenue · Q2-2026$266M+10% y/y
Operating Income · Q2-2026$18M+21% y/y
Net Income · Q2-2026$13M+178% y/y
Diluted EPS · Q2-2026$0.30+150% y/y
Adjusted Operating Income · Q2-2026$48M+17% y/y
Adjusted Diluted EPS · Q2-2026$0.89+17% y/y
Adjusted EBITDA · Q2-2026$61M+16% y/y
Operating cash flow · Q2-2026$65M+330% y/y
Year-to-date operating cash flow · H1-2026$117M+149% y/y
Adjusted Gross Margin · Q2-202647.0%

Guidance

Q3 2026 revenue $300-304M (>21% growth); adjusted EBITDA $74-77M; adjusted diluted EPS $0.95-1.00. FY2026 revenue $1,130-1,140M (>15% growth); adjusted EBITDA $273-278M (>24% growth); adjusted diluted EPS $3.68-3.74 (>12% growth).

Guidance raised for Q3 and FY2026, incorporating Riverpoint Medical acquisition; strong momentum across portfolio

Risks flagged

Integration risk from Riverpoint Medical acquisition

“Acquisition integration risk; financial projections not subject to same accounting oversight”

Foreign exchange exposure

“Guidance assumes no significant changes in foreign exchange rates; FX favorably impacted revenue by $2.4M”

Tariff and trade policy risk

“Exposure to increased tariffs, trade restrictions or taxes on products”
Read the original on SEC EDGAR ↗
27 Jul 20268-K · 2.01, 2.03, 7.01Closing Consideration $1.20B; Milestone Payment $250M; Borrowings under Credit Agreement $616Macquisitionopen

Figures in the filing · each found in the filing text

Closing Consideration · Q2-2026$1.20B
Milestone Payment · Q2-2026$250M
Borrowings under Credit Agreement · Q2-2026$616M
Consolidated Debt · Q2-2026$855M

Risks flagged

Increased leverage from debt-financed acquisition.

“Debt increased to $854.7M from $616M borrowing.”
Read the original on SEC EDGAR ↗
9 Jun 20268-K · 1.01, 3.02, 8.01Novanta Inc. filed an 8-K regarding a private placement of unregistered shares, indicating equity dilution. The filing includes a Securities Purchase Agreement and Registration Rights Agreement, but no specific dollar amount or share countopen

Risks flagged

Dilution of existing shareholders by ~5.7%.

“Based on 35,613,303 Common Shares outstanding... and an additional 4,717,185 Common Shares... there would be an aggregate of 42,473,345 Common Shares outstanding... following the Closing.”
Read the original on SEC EDGAR ↗
9 Jun 20268-K · 1.01, 7.01Novanta announces acquisition of Riverpoint Medical for $1.2B upfront plus $250M milestone, expanding into minimally invasive surgery consumables, doubling recurring medical consumables revenue to ~$300M, immediately accretive to margins anacquisitionopen

Risks flagged

Increased leverage from financing acquisition with credit facilities and equity issuance.

“The Transaction will be financed through a combination of cash on hand, the Company’s existing credit facilities... and proceeds from the Company’s equity issuance announced today.”
Read the original on SEC EDGAR ↗
15 May 20268-K · 1.01, 2.03Novanta entered into a Second Amendment to its credit agreement, establishing $200M delayed draw term loan commitments maturing June 2030, with interest based on leverage ratio.open

Risks flagged

Increased debt capacity may lead to higher leverage if drawn.

“The Delayed Draw Term Loans will mature on June 27, 2030 and shall bear interest... plus a margin.”
Read the original on SEC EDGAR ↗
11 May 202610-QTotal Revenue $258M (+10% y/y); Automation Enabling Technologies Revenue $131M (+7% y/y); Medical Solutions Revenue $126M (+15% y/y)open

Figures in the filing · each found in the filing text

Total Revenue · Q1-2026$258M+10% y/y
Automation Enabling Technologies Revenue · Automation Enabling Technologies · Q1-2026$131M+7% y/y
Medical Solutions Revenue · Medical Solutions · Q1-2026$126M+15% y/y
Gross Profit Margin · Q1-202644.1%
Operating Income · Q1-2026$28M-15% y/y
Operating Cash Flow · Q1-2026$52M+63% y/y
Diluted EPS · Q1-2026$0.51-14% y/y

Risks flagged

Tariff-driven margin compression

“Tariffs imposed by the U.S. government on imports from certain countries, including China, have increased our cost of revenue and contributed to gross margin compression in both of our reportable segments during the three months ended April 3, 2026.” · word for word

Geopolitical conflict supply chain risk

“the conflict arising from coordinated US and Israeli military strikes on Iran beginning in February 2026, and Iran's subsequent retaliatory actions, including the temporary closure of the Strait of Hormuz, has contributed to increased global energy prices, heightened supply chain uncertainty, and rising freight and commodity costs.” · word for word
Read the original on SEC EDGAR ↗
11 May 20268-K · 2.02Novanta Q1 2026 revenue $257.7M (+10.4% YoY), bookings +37% YoY, book-to-bill 1.10, Adj. EBITDA +14.2% to $57.1M, Adj. EPS +9.5% to $0.81. Raised Q2 organic growth guidance to 6-8%.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$258M+10% y/y
Adjusted EBITDA · Q1-2026$57M+14% y/y
Adjusted Diluted EPS · Q1-2026$0.81+9% y/y
GAAP Diluted EPS · Q1-2026$0.51-14% y/y
Net Income · Q1-2026$21M-0% y/y
Operating Cash Flow · Q1-2026$52M+63% y/y
Organic Revenue Growth · Q1-20263.1%
Bookings Growth · Q1-202637.0%
Book-to-Bill Ratio · Q1-2026$1.10

Guidance

Q2 2026 GAAP revenue $259-264M; Adj. EBITDA $58-62M; Adj. EPS $0.81-0.86. FY26 GAAP revenue $1,040-1,055M; Adj. EBITDA $245-250M; Adj. EPS $3.50-3.65. Q2 organic growth 6-8% (vs Q1 organic 3.1%).

Raised Q2 organic growth guidance to 6-8% from Q1's 3.1% actual, supported by strong bookings and backlog. Full-year guidance implies continued momentum.

Risks flagged

Trade and economic climate uncertainty could impact demand

“rigorously executing in a dynamic trade and economic climate” · word for word

GAAP operating income declined due to acquisition-related costs

“GAAP operating income was $27.5 million, compared to $32.4 million in the prior year” · word for word
Read the original on SEC EDGAR ↗
24 Apr 2026DEF 14AAnnual proxy statement disclosing executive compensation, governance, and 2025 financial results.open

Figures in the filing · each found in the filing text

Revenue · FY2025$981M+3% y/y
Net Income · FY2025$54M-16% y/y
Adjusted EBITDA · FY2025$221M+5% y/y
Operating Cash Flow · FY2025$64M-60% y/y
Organic Revenue Growth · FY2025-0.5%

Risks flagged

Operating cash flow decline

“Operating cash flow was $64.1 million for fiscal year 2025, a decrease of $94.4 million from $158.5 million for fiscal year 2024.” · word for word

Negative organic revenue growth

“Organic Revenue Growth was (0.5)% for the fiscal year 2025.” · word for word

Underperformance vs. peers

“Total Shareholder Return Year Ended December 31, 2025 Novanta Inc. -22 % Russell 2000 Index 13 %” · word for word
Read the original on SEC EDGAR ↗
23 Feb 202610-KRevenue $981M (+3% y/y); Automation Enabling Technologies Revenue $501M (+2% y/y); Medical Solutions Revenue $480M (+5% y/y)open

Figures in the filing · each found in the filing text

Revenue · FY2025$981M+3% y/y
Automation Enabling Technologies Revenue · Automation Enabling Technologies · FY2025$501M+2% y/y
Medical Solutions Revenue · Medical Solutions · FY2025$480M+5% y/y
Gross Profit Margin · FY202544.4%
Net Income · FY2025$54M-16% y/y
Total Debt · 2025-12-31$260M
R&D Expense · FY2025$95M0% y/y
SG&A Expense · FY2025$196M+11% y/y

Risks flagged

Customer Concentration

“Our top ten customers accounted for approximately 42% of our sales for the year ended December 31, 2025.” · word for word

Foreign Exchange Exposure

“In the event of a decline in the value of the Euro, British Pounds, Chinese Yuan or Japanese Yen, we typically experience a decline in our revenues and profit margins.” · word for word

Intangible Asset Impairment Risk

“As of December 31, 2025, we had $828.1 million of net intangible assets, including goodwill, on our consolidated balance sheet.” · word for word
Read the original on SEC EDGAR ↗
23 Feb 20268-K · 2.02Revenue $258M (+8% y/y); Adjusted Diluted EPS $0.91 (+20% y/y); Adjusted EBITDA $61M (+17% y/y); Guidance: FY2026 revenue guidance $1.03-1.05B vs FY2025 $981M; Adj. EBITDA $245-250M vs $221M; Adj. EPS $3.50-3.65 vs $3.29earningsopen

Figures in the filing · each found in the filing text

Revenue · Q4-2025$258M+9% y/y
Adjusted Diluted EPS · Q4-2025$0.91+20% y/y
Adjusted EBITDA · Q4-2025$61M+17% y/y
GAAP Diluted EPS · Q4-2025$0.45-2% y/y
Operating Cash Flow · Q4-2025$9M-86% y/y
Bookings Growth · Q4-202525.0%
Book-to-Bill · Q4-2025$1.11
Total Debt · FY2025$251M

Guidance

FY2026 revenue guidance $1.03-1.05B vs FY2025 $981M; Adj. EBITDA $245-250M vs $221M; Adj. EPS $3.50-3.65 vs $3.29

Management raised FY2026 guidance across all key metrics, citing strong bookings, new product momentum, and margin improvement from operational initiatives.

Risks flagged

Temporary operating cash flow pressure from regionalization strategy

“Operating cash flow was $8.8 million, compared to $61.6 million in the prior year. The year-over-year decrease in operating cash flow was primarily driven by the Company’s strategy to regionalize manufacturing, which resulted in temporary increases in net working capital.” · word for word

Trade cost and disruption exposure

“regionalize manufacturing to mitigate the effects of trade costs and disruptions on our customers when purchasing Novanta’s products” · word for word
Read the original on SEC EDGAR ↗
1 Dec 20258-K · 7.01Novanta appointed Alexander Manganiello as General Counsel and Corporate Secretary, effective December 1, 2025. He brings 30 years of legal experience from Vertex and Pfizer.SEC ↗
13 Nov 20258-K · 7.01Novanta revised Q4 and FY2025 adjusted diluted EPS guidance downward to reflect equity issuance dilution; revenue and EBITDA guidance unchanged.open

Figures in the filing · each found in the filing text

Revenue · Q4-2025$253M
Revenue · FY2025$975M
Adjusted EBITDA · Q4-2025$62M
Adjusted EBITDA · FY2025$222M
Adjusted Diluted EPS · Q4-2025$0.84-3% y/y
Adjusted Diluted EPS · FY2025$3.21-1% y/y

Guidance

Q4 2025 Adjusted Diluted EPS revised to $0.84-$0.91 from $0.87-$0.93; FY2025 revised to $3.21-$3.28 from $3.24-$3.30. Revenue and EBITDA guidance unchanged.

EPS guidance cut due to share dilution from equity issuance; operational guidance unchanged.

Risks flagged

EPS dilution from equity issuance; no change to revenue or EBITDA guidance.

“Guidance revision reflects share count increase from equity issuance, not operational deterioration.”
Read the original on SEC EDGAR ↗
12 Nov 20258-K · 1.01, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageopen

Risks flagged

Dilution risk from equity offering

“Tangible equity units offering may dilute existing shareholders if converted to equity.”

Debt obligation increase

“Item 2.03 indicates creation of a direct financial obligation.”
Read the original on SEC EDGAR ↗
3 Nov 20258-K · 2.02Revenue $248M (+1% y/y); GAAP Net Income $11M; Adjusted EBITDA $58M; Guidance: Q4 revenue $253M-$257M; FY2025 revenue $975M-$979Mearningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$248M+1% y/y
GAAP Net Income · Q3-2025$11M
Adjusted EBITDA · Q3-2025$58M
Adjusted Diluted EPS · Q3-2025$0.87
GAAP Diluted EPS · Q3-2025$0.30
Operating cash flow · Q3-2025$9M
Book-to-bill · Q3-2025$1.03
Bookings growth · Q3-202517.0%

Guidance

Q4 revenue $253M-$257M; FY2025 revenue $975M-$979M

Q4 guidance implies return to year-over-year organic growth; FY2026 mid-single digit organic growth expected.

Risks flagged

Operating cash flow declined to $8.5M from $23.0M due to inventory purchases and restructuring.

“Operating cash flow for the third quarter of 2025 was $8.5 million, compared to $23.0 million for the third quarter of 2024.” · word for word

Organic revenue growth negative at -3.8%.

“Organic Revenue Growth... was (3.8)% for the third quarter of 2025”
Read the original on SEC EDGAR ↗
3 Nov 202510-QNovanta reported Q3 2025 revenue +1.4% YoY (acquisition-driven), operating income -32.9% YoY, and diluted EPS $0.30 vs $0.53. Gross margin improved slightly; SG&A and restructuring costs weighed on profitability.earningsopen

Figures in the filing · each found in the filing text

Total revenue · Q3-2025$248M+1% y/y
Gross profit margin · Q3-202544.8%
Operating income · Q3-2025$22M-33% y/y
Diluted EPS · Q3-2025$0.30-43% y/y
Total revenue · 9M-2025$722M+2% y/y
Operating cash flow · 9M-2025$55M-43% y/y
Cash and cash equivalents · 2025-09-26$89M

Risks flagged

Tariff and trade policy uncertainty

“Economic tensions and changes in trade policies, such as higher tariffs, retaliatory measures, renegotiated free trade agreements, changes in government funding, and the ongoing impact from prolonged inflationary pressures have impacted the global market for our products and the cost to manufacture.” · word for word

Restructuring execution risk

“We recorded restructuring, acquisition, and related costs of $6.7 million during the three months ended September 26, 2025, versus $2.5 million during the prior year period.” · word for word

ERP implementation disruption

“The increase in SG&A expenses, both in total dollars and as a percentage of revenue, was primarily driven by costs associated with planning and design phase of our enterprise resource planning (“ERP”) system implementation.” · word for word

Foreign exchange exposure

“Foreign exchange transaction gains (losses) were $(3.1) million for the nine months ended September 26, 2025 and $(0.8) million for the prior year period.” · word for word
Read the original on SEC EDGAR ↗

Novanta Inc. — questions

What did Novanta Inc. file recently?
16 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-05 — Novanta reported Q2 2026 revenue of $265.8M (+10.3% YoY) and operating income of $18.1M (+21.1% YoY), with strong growth in both segments and a major acquisition of Riverpoint Medical.

Every figure on this page comes from Novanta Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.